Global

Who We Are

The CSL Behring story spans decades of innovation, collaboration, patient focus, and an ongoing drive for excellence.

Learn more about us here.
Product Overview
CSL Behring develops, manufactures and markets protein based therapies, including:
Bleeding Disorders Therapies
Fluid Replacement Therapies
Hereditary Angioedema (HAE) Therapies
Immunoglobulin Therapies
Pulmonary Therapies
Wound Healing Therapies
Global Product Portfolio
Features
World PI Week
World PI Week
CSL Behring: Benefactor
Key Issues Dialogue Series
Dialogue
Pros and Cons of Albumin Use in Fluid Management
Personal Stories
Personal Stories
Shari Starr’s Journey to an HAE Diagnosis
Public Policy Update-US
Policy Impact
Public Policy Update-US
News
04-May-2012
4-Factor PCC Safety Profile Consistent With US Standard of Care
04-May-2012
Study Shows 4-Factor PCC As Effective As US Standard of Care
03-May-2012
CSL Behring Launches Study of C1-INH as SubQ Formulation
18-Apr-2012
Feature Story: Journey to a VWD Diagnosis
18-Apr-2012
HealthyWomen Asks: Do You Know the Signs of VWD?
View all news